Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "medicines"

1338 News Found

Briefs: Shilpa Medicare and Medico Remedies
News | October 07, 2025

Briefs: Shilpa Medicare and Medico Remedies

Medico Remedies receives order worth US$ 1,781,000


India invites applications under PRIP scheme to drive pharma-medtech innovation
R&D | October 06, 2025

India invites applications under PRIP scheme to drive pharma-medtech innovation

Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance


Lilly to invest $1 billion+ in new contract manufacturing in India
News | October 06, 2025

Lilly to invest $1 billion+ in new contract manufacturing in India

Investment to expand manufacturing and global medicine supply capacity


BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease
Drug Approval | October 05, 2025

BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease


Novartis to launch DTP platform for Cosentyx in US
Supply Chain | October 01, 2025

Novartis to launch DTP platform for Cosentyx in US

Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers


Pfizer agrees to slash prescription drug prices for Americans
News | October 01, 2025

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%


AbbVie begins construction of $70 million biologics manufacturing site in US
News | October 01, 2025

AbbVie begins construction of $70 million biologics manufacturing site in US

The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology